Endo Int'l (NASDAQ: ENDP) announced that the U.S. Food and Drug Administration (FDA) has approved a label update for XIAFLEX ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Piper Jaffray Raises Price Target on Endo Int'l (ENDP) Leading up to Par Pharma Acquisition May 19, 2015 7:42 AM Endo Int'l (ENDP) to Acquire Par Pharma in ~$8.05B DealMay 18, 2015 6:32 AM Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry LeaderMay 18, 2015 6:30 AM Endo Announces Updated XIAFLEX® Label with Recurrence and Retreatment Data in Patients with Dupuytren's ContractureMay 15, 2015 5:38 PM